



VIRTUAL CONNECTIONS. REAL VALUE.



LYTHAM
PARTNERS

SUMMER 2022 INVESTOR CONFERENCE

CONFERENCE PACKET | JUNE 21 - 22, 2022

www.lythampartners.com/virtual

VIRTUAL CONNECTIONS. REAL VALUE.

WHO WE ARE.

Lytham Partners is one of the country's leading investor relations firms. With more than two decades of Corporate Access experience, we have built one of the industry's most diverse and effective platforms for connecting small cap companies with high quality and focused institutional investors.

OUR MISSION.

The mission of the Lytham Partners Investor Conference Series is to create value for small cap companies through virtual connections with high-quality institutional investors. Our conference series has featured more than 170 companies from various industries including healthcare & pharma, consumer, technology, industrials & special situations, clean tech, and financial services. Some highlights of our event include virtual 1x1 meetings, webcast presentations, engaging fireside chats and panels on special topics within the industry.



MEETINGS THAT MATTER

We focus on connecting companies with high-quality investors to provide the biggest and best impact. In 2021 alone our conferences connected **150+** companies with **1,000+** investors for over **3,000** 1x1 meetings.



VALUE THAT LASTS

You will continue to reap benefits far past the end of the event. By participating in our conference, your company can get valuable content to help increase awareness and expand your reach among investors and stakeholders.

CONTACT US!

For more information on our Summer 2022 Investor Conference, please call 602.889.9700 or email us at conference@lythampartners.com

COMPANY LIST

P = Presenting Company

Updated as of June 15, 2022.
Participation subject to change

BASIC MATERIALS

- P** Arianne Phosphate (TSXV: DAN / PINK: DRRSF)

CANNABIS

TILT Holdings (NEO: TILT / OTCQX: TLLTF)

CLEANTECH

LiqTech International (NASDAQ: LIQT)

CONSUMER

Else Nutrition Holdings (TSXV: BABY / OTCQB: BABYF)

Global Bioenergies (Euronext Growth: ALGBE)

- P** Reeds, Inc. (NASDAQ: REED)

FINTECH

AppTech Payments Corp. (NASDAQ: APCX)

- P** BIGG Digital Assets (CSE: BIGG / OTCQX: BBKCF)

Mogo Inc. (NASDAQ: MOGO / TSX: MOGO)

- P** TAAL Distributed Information Technologies (CSE: TAAL / OTCQX: TAALF)

Voyager Digital Ltd. (TSE: VOYG / OTCQX: VYGVF)

INDUSTRIALS

- P** GSE Systems Inc. (NASDAQ: GVP)

IBI Group Inc. (TSX: IBG / PINK: IBIBF)

- P** L.B. Foster Company (NASDAQ: FSTR)

S&W Seed Company (NASDAQ: SANW)

SenesTech (NASDAQ: SNES)

COMMUNICATION SERVICES

- P** LiveWorld, Inc. (OTC PINK: LVWD)

HEALTHCARE

Acasti Pharma (NASDAQ: ACST / TSXV: ACST)

- P** Aurora Spine Corp. (TSXV: ASG / OTCQB: ASAPF)

- P** Aytu BioPharma, Inc. (NASDAQ: AYTU)

Aziyo Biologics (NASDAQ: AZYO)

Delcath Systems (NASDAQ: DCTH)

Health Professionals Alliance (Private)

- P** Humanigen, Inc. (NASDAQ: HGEN)

- P** Immucell Corp. (NASDAQ: ICCC)

InfuSystem Holdings Inc. (NYSE American: INFU)

INVO Bioscience (NASDAQ: INVO)

- P** Jaguar Health, Inc. (NASDAQ: JAGX)

- P** MedAvail Holdings, Inc. (NASDAQ: MDVL)

- P** Ontrak, Inc. (NASDAQ: OTRK)

OpSens Inc. (TSX: OPS / OTCQX: OPSSF)

Perimeter Medical Imaging (TSXV: PINK / PINK: PYNKF)

- P** Reliq Health Technologies Inc. (TSXV: RHT / PINK: RQHTF)

- P** Science 37 Holdings, Inc. (NASDAQ: SNCE)

Scientific Industries, Inc. (OTCQB: SCND)

STRATA Skin Sciences (NASDAQ: SSKN)

VolitionRx (NYSE American: VNRX)

TECHNOLOGY

- P** Precision Optics Corporation Inc. (OTCQB: PEYE)

Wayside Technology Group, Inc. (NASDAQ: WSTG)

Zoomd Technologies (TSXV: ZOMD / OTC: ZMDTF)

CONTACT US!

For more information on our Summer 2022 Investor Conference, please call 602.889.9700 or email us at conference@lythampartners.com

COMPANY PROFILES

Market Cap data as of June 1, 2022.
\$ in millions USD

ACASTI PHARMA (NASDAQ: ACST / TSXV: ACST)

Healthcare | Market Cap: \$42M

Alpha Cognition is a clinical stage, biopharmaceutical company dedicated to developing treatments for under-served neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis (ALS). ALPHA-1062, a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials. It is being developed as a new acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type, with minimal gastrointestinal side-effects and novel routes of administration. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS. ALPHA-0602 is patented and has received Orphan Drug Designation from the FDA.

APPTech PAYMENTS CORP. (NASDAQ: APCX)

FinTech | Market Cap: \$22M

AppTech Payments Corp., is a financial technology company, provides electronic payment processing technologies and merchant services in the United States. Its merchant services offer financial processing for businesses to accept cashless payments, such as credit cards, automatic clearing house, and wireless payments. The company's merchant services software offers integrated solutions, such as data encryption, payment tokenization, issuing banking authorization, and the creation of white-label and merchant-specific mobile applications for friction less digital and mobile payment acceptance, including acceptance of alternative payment methods, as well as multi-use case, multi-channel, API-driven, and account-based issuer processing for card, digital tokens, and payment transfer transactions. It is developing mobile payment platform relies on SMS text messaging.

ARIANNE PHOSPHATE (TSXV: DAN / PINK: DRRSF)

Basic Materials | Market Cap: \$104M

Arianne Phosphate ("Arianne Phosphate Inc.") (www.arianne-inc.com) is developing the Lac à Paul phosphate deposits located approximately 200 km north of the Saguenay/Lac St. Jean area of Quebec, Canada. These deposits will produce a high-quality igneous apatite concentrate grading 39% P₂O₅ with little or no contaminants (Feasibility Study released in 2013). The Company has 185,464,469 shares outstanding.

AURORA SPINE CORP. (TSXV: ASG / OTCQB: ASAPF)

Healthcare | Market Cap: \$21M

Aurora Spine Corporation (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes. Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies. Additional information can be accessed at www.aurora-spine.com or www.aurorapaincare.com.

AYTU BIOPHARMA, INC. (NASDAQ: AYTU)

Healthcare | Market Cap: \$18M

Aytu BioPharma is a pharmaceutical company with a portfolio of commercial prescription therapeutics and consumer health products, and a growing therapeutics pipeline focused on treating rare, pediatric-onset disorders. The company's prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), as well as Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines in various formulations for infants and children with fluoride deficiency. Aytu is also building a therapeutic pipeline, which includes AR101 (enzastaurin), a PKC inhibitor in development for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). VEDS is a rare genetic disease typically diagnosed in childhood resulting in high morbidity and a significantly shortened lifespan, and for which there are no currently approved treatments. AR101 has received Orphan Drug designation and Fast Track designation from the U.S. Food and Drug Administration and has received Orphan Drug designation from the European Commission. Aytu is also researching and advancing the development of the Healight ultraviolet light A (UVA) endotracheal catheter, a patented, investigational medical device with potential application in the treatment of severe, difficult-to-treat respiratory infections.

AZIYO BIOLOGICS (NASDAQ: AZYO)

Healthcare | Market Cap: \$83M

Aziyo Biologics is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. Since its founding in 2015, the Company has created a portfolio of commercial-stage products used in cardiovascular, orthopedic, and reconstructive specialties.

BIGG DIGITAL ASSETS (CSE: BIGG / OTCQX: BBKCF)

FinTech | Market Cap: \$100M

BIGG Digital Assets Inc. (BIGG) believes the future of crypto is a safe, compliant, and regulated environment. BIGG invests in products and companies to support this vision. BIGG has three portfolio companies: Netcoins (netcoins.ca), Blockchain Intelligence Group (blockchaingroup.io) and TerraZero (terrazero.com).

COMPANY PROFILES

Market Cap data as of June 1, 2022.
\$ in millions USD

DELCATH SYSTEMS (NASDAQ: DCTH)

Healthcare | Market Cap: \$43M

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In the United States, the PHP system is being developed under the tradename HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), or HEPZATO, and is considered a combination drug and device product regulated by the United States Food and Drug Administration (FDA). In Europe, the PHP system is regulated as a Class IIb medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver.

ELSE NUTRITION HOLDINGS (TSXV: BABY / OTCQB: BABYF)

Consumer | Market Cap: \$91M

Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the "2017 Best Health and Diet Solutions" award at the Global Food Innovation Summit in Milan. Else Plant-Based Complete Nutrition for Toddlers was recently ranked as the #1 Top seller in the baby and toddler formula category on Amazon. The holding company, Else Nutrition Holdings Inc., is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol OYL. Else's Executives include leaders hailing from leading infant nutrition companies. Many of Else advisory board members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies, and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children's Hospital, Pediatrics at Harvard Medical School, USA, Tel Aviv University, Schneider Children's Medical Center of Israel, Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium.

GLOBAL BIOENERGIES (EURONEXT GROWTH: ALGBE)

Consumer | Market Cap: \$50M

Global Bioenergies has developed a process to convert plant-derived resources into a key family of ingredients used in the cosmetics industry. The process was first developed in a laboratory, where the Company is further enhancing performance. It now operates as a pilot and a demo plant, with the capacity to start breaking into the market, initially through the Company's longwear home make-up brand, launched in 2021. The Company is gradually expanding its production capacities and is looking to improve the environmental footprint of not only the cosmetics industry but also that of other areas such as transportation and materials. Global Bioenergies is listed on Euronext Growth Paris (ALGBE).

GSE SYSTEMS, INC. (NASDAQ: GVP)

Industrials | Market Cap: \$30M

We are the future of operational excellence in the power industry. As a collective group, GSE Solutions leverages top skills, expertise, and technology to provide highly specialized solutions that allow customers to achieve the performance they imagine. Our experts deliver and support end-to-end training, engineering, compliance, simulation, and workforce solutions that help the power industry reduce risk and optimize plant operations. GSE is proven, with over four decades of experience, more than 1,100 installations, and hundreds of customers in over 50 countries spanning the globe. www.gses.com.

HEALTH PROFESSIONALS ALLIANCE (PRIVATE)

Healthcare

Founded in 2018, Health Professionals Alliance provides a suite of personal and professional services intended to empower and preserve the independent doctor. This alliance employs a holistic approach to growth that helps doctors focus on what they do best, caring for their patients.

HUMANIGEN, INC. (NASDAQ: HGEN)

Healthcare | Market Cap: \$165M

Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), is a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called 'cytokine storm'. Lenzilumab is a first-in class antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). Results from preclinical models indicate GM-CSF is an upstream regulator of many inflammatory cytokines and chemokines involved in the cytokine storm. Early in the COVID-19 pandemic, investigation showed high levels of GM-CSF secreting T cells were associated with disease severity and intensive care unit admission. Humanigen's Phase 3 LIVE-AIR study suggests early intervention with lenzilumab may prevent consequences of a full-blown cytokine storm in hospitalized patients with COVID-19. Humanigen is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 and CD19-targeted CAR-T cell therapies and is also exploring the effectiveness of lenzilumab in other inflammatory conditions such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation, eosinophilic asthma, and rheumatoid arthritis. The PREACH-M study in chronic myelomonocytic leukemia being conducted at 5 centers in Australia has begun dosing patients. Both the SHIELD study in CAR-T and the RATinG study in acute Graft versus Host Disease (aGvHD) are planned to begin enrolling in the first half of 2022, in the US and the UK respectively. Additional COVID studies which will be completed or initiated in 2022 include the NIH-sponsored ACTIV-5/BET-B study in the US and Korea and the C-SMART study being conducted in Australia. All are late-stage, clinical studies. In addition, Humanigen is progressing a Phase 1 program focused on ifabotuzumab in solid tumors.

COMPANY PROFILES

Market Cap data as of June 1, 2022.
\$ in millions USD

IBI GROUP (TSX: IBC / PINK: IBIBF)

Industrials | Market Cap: \$361M

IBI Group Inc. is a technology-driven design firm with global architecture, engineering, planning, and technology expertise spanning over 60 offices and 3,000 professionals around the world. For nearly 50 years, its dedicated professionals have helped clients create livable, sustainable, and advanced urban environments. IBI Group believes that cities thrive when designed with intelligent systems, sustainable buildings, efficient infrastructure, and a human touch.

IMMUCELL (NASDAQ: ICCG)

Healthcare | Market Cap: \$63M

ImmuCell Corporation's (Nasdaq: ICCG) purpose is to create scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets First Defense®, providing Immediate Immunity™ to newborn dairy and beef calves, and is in the late stages of developing Re-Tain®, a novel treatment for subclinical mastitis in dairy cows without a milk discard requirement that provides an alternative to traditional antibiotics.

INFUSYSTEM HOLDINGS, INC. (NYSE AMERICAN: INFU)

Healthcare | Market Cap: \$174M

InfuSystem Holdings, Inc. is a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-platform model. The lead platform is Integrated Therapy Services ("ITS"), providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The ITS segment is comprised of Oncology, Pain Management, Wound Therapy and Lymphedema businesses. The second platform, Durable Medical Equipment Services ("DME Services"), supports the ITS platform and leverages strong service orientation to win incremental business from its direct payer clients. The DME Services segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Headquartered in Rochester Hills, Michigan, the Company delivers local, field-based customer support and also operates Centers of Excellence in Michigan, Kansas, California, Massachusetts, Texas and Ontario, Canada.

INVO BIOSCIENCE (NASDAQ: INVO)

Healthcare | Market Cap: \$13M

We are a medical device company focused on creating simplified, affordable treatments for patients diagnosed with infertility. Our solution, the INVO® Procedure, is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell®, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell® is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase the availability of care.

JAGUAR HEALTH, INC. (NASDAQ: JAGX)

Healthcare | Market Cap: \$31M

Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Jaguar Animal Health is a tradename of Jaguar Health. Jaguar Health's wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance. Crofelemer is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy. Jaguar Health is the majority shareholder of Napo Therapeutics S.p.A., an Italian corporation established by Jaguar Health in Milan, Italy in 2021 that focuses on expanding crofelemer access in Europe. In December of 2021, FDA granted conditional approval of Canalevia™-CA1 (crofelemer), Jaguar Animal Health's oral plant-based prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Canalevia™-CA1 is the first and only product indicated for the treatment of CID in dogs to receive any type of approval from the FDA. Crofelemer, the active pharmaceutical ingredient in Mytesi and Canalevia™-CA1, is sustainably derived from the sap, or latex, of the Amazonian tree species Croton lechleri, which has a rich history of medicinal use by Indigenous peoples in the Western Amazon rainforests of South America. For more information about Jaguar Health, please visit <https://jaguar.health>. For more information about Napo Pharmaceuticals, visit www.napopharma.com. For more information about Napo Therapeutics, visit www.napotherapeutics.com.

L.B. FOSTER COMPANY (NASDAQ: FSTR)

Industrials | Market Cap: \$138M

Founded in 1902, L.B. Foster Company is a global solutions provider of engineered, manufactured products and services that builds and supports infrastructure. The Company's innovative engineering and product development solutions address the safety, reliability, and performance needs of its customer's most challenging requirements. The Company maintains locations in North America, South America, Europe, and Asia. For more information, please visit www.lbfoster.com.

COMPANY PROFILES

Market Cap data as of June 1, 2022.
\$ in millions USD

LIQTECH INTERNATIONAL (NASDAQ: LIQT)

CleanTech | Market Cap: \$13M

LiqTech International, Inc., a Nevada corporation, is a clean technology company that provides state-of-the-art ceramic silicon carbide filtration technologies for gas and liquid purification. LiqTech's silicon carbide membranes are designed to be used in the most challenging water purification applications and its silicon carbide filters are used to control diesel exhaust soot emissions. Using nanotechnology, LiqTech develops products using its proprietary silicon carbide technology, resulting in a wide range of component membranes, membrane systems and filters for both microfiltration and ultrafiltration applications. By incorporating LiqTech's SiC liquid membrane technology with the Company's extensive systems design experience and capabilities, LiqTech offers unique, turnkey solutions for the most difficult water purification applications.

LIVEWORLD, INC. (OTC PINK: LVWD)

Communication Services | Market Cap: \$7M

LiveWorld is a digital agency specializing in social media and technology solutions that help companies spark emotional conversations, build stronger customer relationships, and drive behavior change. We live at the intersection of bold creative rooted in strategy that inspires, moderation that activates human interactions, and technology that enriches and scales customer experiences. With over 25 years of making connections, our integrated team leverages our social media DNA to deliver emotion driven behavior change through digital campaigns with a human touch. LiveWorld clients include the number one brands in pharmaceuticals, healthcare, and financial-travel services. LiveWorld is headquartered in San Jose, California, with an additional office in New York City.

MEDAVAIL HOLDINGS, INC. (NASDAQ: MDVL)

Healthcare | Market Cap: \$119M

MedAvail Holdings, Inc. (NASDAQ: MDVL) is a technology-enabled pharmacy organization, providing turnkey in-clinic pharmacy services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations, to Medicare clinics. MedAvail helps patients to optimize drug adherence, resulting in better health outcomes.

MOGO INC. (NASDAQ: MOGO / TSX: MOGO)

FinTech | Market Cap: \$113M

Mogo is empowering its close to 1.8 million members with simple digital solutions to improve their finances. Through the free Mogo app, consumers can access a digital spending account with Mogo Visa* Platinum Prepaid Card, the only card of its kind in Canada. The MogoCard makes it easy to enjoy spending control while doing good for the planet by planting a tree for every purchase. The Mogo app also enables you to easily buy and sell bitcoin, get free monthly credit score monitoring and ID fraud protection, and access personal loans. Mogo's wholly-owned subsidiary, Carta Worldwide, also offers a digital payments platform that powers the next-generation card programs from innovative fintech companies in Europe, North America and APAC, while Mogo's wholly-owned subsidiary Moka is bringing automated, fully-managed flat-fee investing to Canadians from coast to coast.

ONTRAK, INC. (NASDAQ: OTRK)

Healthcare | Market Cap: \$35M

Ontrak, Inc. is a leading AI and telehealth-enabled healthcare company, whose mission is to help improve the health and save the lives of as many people as possible. Ontrak identifies, engages, activates and provides care pathways to treatment for the most vulnerable members of the behavioral health population who would otherwise fall through the cracks of the healthcare system. We engage individuals with anxiety, depression, substance use disorder and chronic disease through personalized care coaching and customized care pathways that help them receive the treatment and advocacy they need, despite the socio-economic, medical and health system barriers that exacerbate the severity of their comorbid illnesses. The company's integrated intervention platform uses AI, predictive analytics and digital interfaces combined with dozens of care coach engagements to deliver improved member health, better healthcare system utilization, and durable outcomes and savings to healthcare payors.

OPSSENS INC. (TSX: OPS / OTCQX: OPSSF)

Healthcare | Market Cap: \$207M

OpSens Inc. (TSX: OPS) (OTCQX: OPSSF) a cardiology medical device company providing innovative product solutions based on its patented optical technology, focuses mainly on coronary artery stenosis measurement in interventional cardiology. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and excellent lesions access. The OptoWire has been used in the diagnosis and treatment of over 150,000 patients in more than 30 countries. It is approved for sale in the United States, European Union, Japan, and Canada. OpSens is also involved in industrial activities in developing, manufacturing, and installing innovative fiber optic sensing solutions for critical applications.

PERIMETER MEDICAL IMAGING (TSXV: PINK / PINK: PYNKF)

Healthcare | Market Cap: \$92M

With headquarters in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V: PINK) (OTC: PYNKF) (FSE: 4PC) is a medical technology company that is driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. The company's ticker symbol "PINK" is a reference to the pink ribbons used during Breast Cancer Awareness Month, underscoring the company's dedication to helping surgeons, radiologists, and pathologists use Perimeter's imaging technology and AI in the fight against breast cancer, which is estimated to account for 30% of all female cancer diagnoses this year.

COMPANY PROFILES

Market Cap data as of June 1, 2022.
\$ in millions USD

PRECISION OPTICS CORPORATION (OTCQB: PEYE)

Healthcare | Market Cap: \$27M

Founded in 1982, Precision Optics is a vertically integrated optics company primarily focused on leveraging its proprietary micro-optics and 3D imaging technologies to the healthcare and defense/aerospace industries by providing services ranging from new product concept through mass manufacture. Utilizing its leading-edge in-house design, prototype, regulatory and fabrication capabilities as well as its Ross Optical division's high volume world-wide sourcing, inspecting and production resources, the Company is able to design and manufacture next-generation product solutions to the most challenging customer requirements. Within healthcare, Precision Optics enables next generation medical device companies around the world to meet the increasing demands of the surgical community who require more enhanced and smaller imaging systems for minimally invasive surgery as well as 3D endoscopy systems to support the rapid proliferation of surgical robotic systems. In addition to these next generation applications, Precision Optics has supplied top tier medical device companies a wide variety of optical products for decades, including complex endocouplers and specialized endoscopes. The Company is also leveraging its technical proficiency in micro-optics to enable leading edge defense/aerospace applications which require the highest quality standards and the optimization of size, weight and power.

REED'S, INC. (NASDAQ: REED)

Consumer | Market Cap: \$22M

Established in 1989, Reed's is America's best-selling Ginger Beer brand and has been the leader and innovator in the ginger beer category for decades. Virgil's is America's best-selling independent, full line of natural craft sodas. The Reed's Inc. portfolio is sold in over 35,000 retail doors nationwide. Reed's Ginger Beers are unique due to the proprietary process of using fresh ginger root combined with a Jamaican inspired recipe of natural spices and fruit juices. The Company uses this same handcrafted approach in its award-winning Virgil's line of great tasting, bold flavored craft sodas.

RELIQ HEALTH TECHNOLOGIES INC. (TSXV: RHT / PINK: RQHTF)

Healthcare | Market Cap: \$78M

Reliq Health Technologies is a rapidly growing global healthcare technology that specializes in developing innovative Virtual Care solutions for the multi-billion dollar Healthcare market. Reliq's powerful iUGO Care platform supports care coordination and community-based virtual healthcare. iUGO Care allows complex patients to receive high quality care at home, improving health outcomes, enhancing quality of life for patients and families and reducing the cost of care delivery. iUGO Care provides real-time access to remote patient monitoring data, allowing for timely interventions by the care team to prevent costly hospital readmissions and ER visits. Reliq Health Technologies trades on the TSX Venture under the symbol RHT, on the OTC as RQHTF and on the WKN as A2AJTB.

S&W SEED COMPANY (NASDAQ: SANW)

Industrials | Market Cap: \$52M

Founded in 1980, S&W Seed Company is a global integrated seed technology company focused on middle market crops. Headquartered in the United States and with operations in Australia, S&W's vision is to be the world's preferred proprietary seed Company which supplies a range of forage and specialty crop products that supports the growing global demand for animal proteins and healthier consumer diets. S&W is a global leader in proprietary alfalfa, sorghum and pasture seeds, with significant research and development, production and distribution capabilities. S&W's product portfolio also includes hybrid sunflower and wheat and the company is utilizing its research and breeding expertise to develop and produce stevia, the all-natural, zero calorie sweetener for the food and beverage industry.

SCIENCE 37 HOLDINGS, INC. (NASDAQ: SNCE)

Healthcare | Market Cap: \$355M

Science 37 Holdings, Inc.'s (NASDAQ: SNCE) mission is to enable universal access to clinical research—making it easier for patients and providers to participate from anywhere and helping to accelerate the development of treatments that impact patient lives. As a pioneer of decentralized clinical trials, the Science 37 Operating System (OS) supports today's more agile clinical research designs with its full-stack, end-to-end technology platform and centralized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, provider communities, and data and devices. Configurable to enable almost any study type, the Science 37 OS enables up to 21x faster enrollment, 28% better retention, and 3x more diverse patient population with industry-leading workflow orchestration, evidence generation, and data harmonization.

SCIENTIFIC INDUSTRIES, INC. (OTCQB:SCND)

Healthcare | Market Cap: \$32M

Scientific Industries (OTCQB:SCND), is a life science tool provider. It designs, manufactures, and markets laboratory equipment, including the world-renowned Vortex-Genie® 2 Mixer and Torbal® balances, and bioprocessing systems under the product name Cell Growth Quantifier and Liquid Injection System. Scientific Industries' products are generally used and designed for research purposes in laboratories of universities, hospitals, pharmaceutical companies, medical device manufacturers, and pharmacies. To learn more, visit www.scientificindustries.com. **Scientific Bioprocessing, Inc. ("SBI")** is dedicated to providing state-of-the-art instruments, strategies, and technologies to expedite the production of viable cells and therapies with a streamlined process and product consistency. SBI's mission is to develop sensor technologies and instruments that make cell culture and bioprocessing work easier, experiments more reproducible, and culture conditions better suited to meet experimental objectives. SBI is a subsidiary of Scientific Industries Holdings, Inc. To learn more, visit www.scientificbio.com.

SENESTECH (NASDAQ: SNES)

Industrials | Market Cap: \$7M

We are "The Pest Control Difference" for the 21st century. We are rodent fertility control specialists fueled by our passion to create a healthy environment by virtually eliminating rodent pest populations. We keep an inescapable truth in mind. Two rats can be responsible for the birth of up to 15,000 pups a year. We invented ContraPest®, the world's first and only U.S. EPA registered rodent contraceptive. ContraPest® fits seamlessly into all integrated pest management programs, greatly improving the overall goal of effective rodent management. We strive for clean cities, efficient businesses and happy households—all through non-lethal, proactive pest control. At SenesTech, we don't just eliminate rats. We make a better world.

COMPANY PROFILES

Market Cap data as of June 1, 2022.
\$ in millions USD

STRATA SKIN SCIENCES (NASDAQ: SSKN)

Healthcare | Market Cap: \$38M

STRATA Skin Sciences is a medical technology company in dermatology dedicated to developing, commercializing and marketing innovative products for the in-office treatment of dermatologic conditions. Its products include the XTRAC® and Pharos® excimer lasers and VTRAC® lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. The Company's proprietary XTRAC and recently acquired Pharos excimer lasers deliver a highly targeted therapeutic beam of UVB light to treat psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma, diseases which impact over 31 million patients in the United States alone. The technology is covered by multiple patents. STRATA's unique business model in the US leverages targeted Direct to Consumer (DTC) advertising to generate awareness and utilizes its in-house call center and insurance advocacy teams to increase volume for the Company's partner dermatology clinics.

TAAL DISTRIBUTED INFORMATION TECHNOLOGIES (CSE: TAAL / OTCQX: TAALF)

FinTech | Market Cap: \$61M

TAAL Distributed Information Technologies Inc. is a vertically integrated blockchain technology company. It is engaged in the ownership and management of scalable professional-grade Blockchain Infrastructure upon which it strives to deliver value-added services supporting and enabling businesses to build customized blockchain-based solutions and applications for enterprise clients. TAAL's business model drives revenue by granting access to, and enabling the utilization of, a variety of proprietary products, Blockchain Infrastructure, platforms, licenses, and services. Blockchain networks need to support limitless scalability, unbounded transactional volume, and profits earned by those that process the most transactions (as opposed to operations with the highest Hashrate). TAAL has focused its attention and resources on the Bitcoin Satoshi Vision ("BSV") network protocol due to its highly scalable platform and lowest industry cost for developing fiat-based revenue. TAAL is dedicated to the BSV blockchain and supporting enterprises who build their custom cloud-based processing of blockchain data and transaction processing for use upon the BSV blockchain.

TILT HOLDINGS (NEO: TILT / OTCQX: TLLTF)

Cannabis | Market Cap: \$71M

TILT helps cannabis businesses build brands. Through a portfolio of companies providing technology, hardware, cultivation and production, TILT services brands and cannabis retailers across 37 states in the U.S., as well as Canada, Israel, South America, and the European Union. TILT's core businesses include Jupiter Research LLC, a wholly-owned subsidiary and leader in the vaporization segment focused on hardware design, research, development and manufacturing; and cannabis operations, Commonwealth Alternative Care, Inc. in Massachusetts, Standard Farms LLC in Pennsylvania, Standard Farms Ohio, LLC in Ohio, and its partnership with the Shinnecock Indian Nation in New York. TILT is headquartered in Phoenix, Arizona.

VOLITIONRX (NYSE AMERICAN: VNRX)

Healthcare | Market Cap: \$200M

Volition is a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring. Volition's research and development activities are centered in Belgium, with a small laboratory in California and additional offices in Texas, London, and Singapore, as the company focuses on bringing its diagnostic and disease monitoring products to market. For more information about Volition, visit Volition's website volition.com.

VOYAGER DIGITAL LTD. (TSE: VOYG / OTCQX: VYGVF)

FinTech | Market Cap: \$491M

Voyager Digital is one of the fastest growing centralized cryptocurrency platforms in the United States. Voyager is centered around bringing "crypto to all," by making the ability to participate in the rapidly expanding world of crypto as easy and as rewarding as possible for as many people as possible. As of December 31, 2021, Voyager had 3.2 million verified users, 1.1 million funded accounts, and \$5.6 billion of assets on platform. Voyager offers over 100 different digital assets to buy, hold and trade through an award-winning, easy-to-use mobile app. It also offers an industry-leading loyalty program as well as a debit card based on the digital dollar (USDC). In 2022, Voyager will continue to innovate on behalf of crypto consumers through product, service and geographic expansion.

WAYSIDE TECHNOLOGY GROUP, INC. (NASDAQ: WSTG)

Technology | Market Cap: \$153M

Wayside Technology Group is an IT channel company providing both distribution and cloud technology solutions through its Climb, TechXtend, Grey Matter and Cloud Know How operating segments.

ZOOMD TECHNOLOGIES (TSXV: ZOMD / OTC: ZMDTF)

Technology | Market Cap: \$34M

Zoomd offers a site search engine to publishers, and a mobile app user acquisition platform, integrated with a majority of global digital media, to advertisers. The platform unifies more than 600 media sources into one unified dashboard. Offering advertisers, a user acquisition control center for managing all new customer acquisition campaigns using a single platform. By unifying all these media sources onto a single platform, Zoomd saves advertisers significant resources that would otherwise be spent consolidating data sources, thereby maximizing data collection and data insights while minimizing the resources spent on the exercise. Further, Zoomd is a performance-based platform that allows advertisers to advertise to the relevant target audiences using a key performance indicator algorithm that is focused on achieving the advertisers' goals and targets.

DISCLAIMER / DISCLOSURES

Services: Lytham Partners, LLC ("Lytham") provides a range of investor relations services to its clients. The particular services provided vary by client and may change from time to time. Compensation Information: Lytham is compensated by its clients for providing investor relations services. Click here for full compensation information: <https://lythampartners.com/disclosures/>. No Investment Advice: Lytham is not a registered broker-dealer, registered investment adviser or financial adviser, nor does it hold itself out to be. All materials presented on Lytham's website and/or publications or presentations released by Lytham to the public through its website, email, or any other means of transmission are not to be regarded as investment advice, do not constitute an endorsement of the company, and are only for informative purposes. Before making a purchase or sale of any securities mentioned in Lytham's publications or presentations or on its website, Lytham strongly encourages and recommends consultation with a registered securities representative. Lytham's website and/or publications or presentations released by Lytham to the public through its website, email, or any other means of transmission do not constitute an offer to purchase or sell securities, and is not to be construed as a representation of an offer or a solicitation of any offer by Lytham or its client companies to purchase or sell any security. Lytham or any of its affiliates, members, employees, clients, officers, directors, and/or their respective families may from time to time purchase or sell, as agents or principals, or otherwise hold positions in, securities of its client companies, and are free to buy or sell those positions at will. Any such positions may be increased or decreased from time to time in the future without notice. Any information or opinions expressed on Lytham's website and/or publications or presentations released by Lytham are subject to change without notice. Lytham's full disclaimer/disclosures statement can be found on its website at <https://lythampartners.com/disclosures/>.

CONTACT US!

For more information on our Summer 2022 Investor Conference, please call 602.889.9700 or email us at conference@lythampartners.com